Worse than We Thought: Pathogenic Priming Likely Far More Widespread Due to Pseudouridine in Altered Spike mRNA Injections

Rogue proteins not intended from spike mRNA are candidates for molecular mimicry

The novel mRNA vaccine technology given emergency use authorization is now known to be fraught with risks - some of which were foretold before the production of specific mRNA injectables. These vaccines, which include those developed by Moderna and Pfizer-BioNTech, are supposed to work by delivering genetic instructions to our cells, instructing them to produce a piece of the virus known as the spike protein. This, in turn, triggers an immune response, preparing the body to fight the real virus if it later enters the body. One of the first peer-reviewed studies to alert to the problem of using spike protein was my own, published in April 2020, in which I introduced the concept, now known as pathogenic priming.

The process of pathogenic priming refers to the possibility that exposure to a vaccine could, in some cases, enhance the disease in the vaccinated upon subsequent repeated exposures to the same offending epitopes via infection - or follow-up injection. The process has raised concerns within the scientific community: it has been challenged and validated in the lab, and it has been cited hundreds of times.

One specific aspect of mRNA vaccine technology that could potentially contribute to pathogenic priming is the use of pseudouridine, a synthetic modification introduced to increase the stability of the mRNA and its acceptance by the human immune system.

Recent research has highlighted a fatal flaw in mRNA technology that impairs the process of protein translation process from mRNA within human cells. This problem involves a well-known issue of frameshifting, where the reading frame of the mRNA is altered due to slippage of the translational machinery on the pseudouridine, resulting in the production of unintended and abnormal proteins, colloquially referred to as "rogue proteins."

These rogue proteins themselves represent a population of proteins with additional opportunities for happenstance matches in 3D to human proteins, thus training and confusing antibodies to attack human tissues via self-reactive antibodies. Thus, mRNA vaccine-related pathogenic priming is likely far worse than originally anticipated, as the number and types of epitopes the immune system will train to have nothing to do with SARS-CoV-2 immunity - leading to major off-target deviations from the intended immune response elicited by the vaccine.

This article aims to explore the intricate relationship between pseudouridine-induced frameshifting and the production of rogue proteins in the context of mRNA vaccines. By focusing on the scientific evidence surrounding frameshifting, the nature of the rogue proteins produced, and their potential implications for vaccine safety and efficacy, we seek to provide a comprehensive understanding of this critical issue. As we navigate the complexities of mRNA vaccine technology, it is essential to balance the immense benefits these vaccines offer in controlling infectious diseases with the ongoing need to ensure their safety for all individuals.

Understanding mRNA Vaccines and Pseudouridine

mRNA vaccines represent an entirely novel approach in public health’s attempts to fight against infectious diseases. They are supposed to use our body's cellular machinery to produce a viral antigen, which is then supposed to stimulate a precise immune response. This method contrasts traditional vaccines, which often use weakened or inactivated forms of a virus. The heart of mRNA vaccine technology lies in its use of messenger RNA (mRNA) strands, which carry the genetic instructions for cells to produce the virus's spike protein, mimicking an infection and prompting the immune system to respond.

Both Pfizer and Moderna chose to use pseudouridine to replace uridine, one of the four standard nucleosides in RNA, ostensibly to evade the body's innate immune response to foreign RNA. This modification allows the mRNA strand to enter cells and produce the viral protein without being prematurely destroyed by the body's defenses.

However, we now know (Mulroney et al., 2023) that the introduction of pseudouridine brings about an unintended consequence in about 1/4 of jab recipients: frameshifting during the protein translation process. Frameshifting occurs when the ribosome, the cellular machinery responsible for translating mRNA into protein, misreads the mRNA sequence. This misreading leads to the production of proteins that are different from the intended viral antigen. These aberrant proteins, or "rogue proteins," are a new rich source of irrelevant epitopes, each one of which could potentially create new-onset molecular mimicry, a phenomenon where the rogue proteins closely resemble self-proteins within the human body.

Molecular mimicry raises concerns about autoimmunity, a condition where the immune system mistakenly attacks the body's own cells, tissues, or organs. Our bodies produce something like 600,000 peptide sequences, so the numbers say that each reactive antibody to rogue proteins has a decent chance for a match to human proteins. The similarity between rogue proteins produced due to frameshifting and the body's natural proteins could lead to myriad, diffuse autoimmune priming events.

The immune system, primed by the vaccine to attack the rogue proteins, will fail to distinguish between some of these proteins and the body's own proteins, leading to an attack on healthy cells. This mechanism of autoimmunity (driven by molecular mimicry rather than the immune-escape feature of pseudouridine), highlights a complex risk associated with mRNA vaccines. It underscores the need for a deeper understanding of how pseudouridine-induced frameshifting might contribute to the development of autoimmunity, potentially increasing the risk of disease following vaccination.

Operation Warp Speed was a Massively Morbid and Fatal Mistake

Hopefully, public health and pharma have learned a lesson: taking shortcuts with clinical research on drugs and vaccines can lead to massively fatal implications. Whether such mass casualty events matter is a measure of our degree of humanity. I am committed to making sure - whatever comes in our future - that knowledge is based on appropriately and carefully conducted science, not pipedreams and denialism.

RELATED:

An QJ, Qin DA, Pei JX. Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother. 2021 Sep 2;17(9):2954-2956. doi: 10.1080/21645515.2021.1920274. Epub 2021 May 25. PMID: 34033732; PMCID: PMC8381833.

Cozzani E, Gasparini G, Sticchi L, Russo R, Icardi G, Parodi A. Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases. Eur J Dermatol. 2021 Jun 1;31(3):415-417. doi: 10.1684/ejd.2021.4043. PMID: 34309530; PMCID: PMC8354837.

Lerner A, Benzvi C, Vojdani A. SARS-CoV-2 Gut-Targeted Epitopes: Sequence Similarity and Cross-Reactivity Join Together for Molecular Mimicry. Biomedicines. 2023 Jul 7;11(7):1937. doi: 10.3390/biomedicines11071937. PMID: 37509576; PMCID: PMC10376948.

Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020 Apr 9;3:100051. doi: 10.1016/j.jtauto.2020.100051. PMID: 32292901; PMCID: PMC7142689.

Mulroney, T. E., et al. (2023). N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature. doi.org/10.1038/s41586-023-06800-3.

Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, Gillespie J. 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines. 2023 Aug 17;11(8):2287. doi: 10.3390/biomedicines11082287. PMID: 37626783; PMCID: PMC10452662.

TELEGRAPH: One in four who had Pfizer Covid jabs experienced unintended immune response https://www.telegraph.co.uk/news/2023/12/06/mrna-jabs-modena-pfizer-quarter-unintended-response/#selection-2367.0-2367.163

Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021 Jan 19;11:617089. doi: 10.3389/fimmu.2020.617089. PMID: 33584709; PMCID: PMC7873987.